Boehringer Ingelheim’s Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype

 Boehringer Ingelheim’s Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype

Boehringer Ingelheim’s Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype

Shots:

  • The FDA’s approval is based on P-III INBUILD study assessing Ofev (150mg, bid) vs PBO in 663 patients with chronic fibrosing ILDs with a progressive phenotype for 52wks. at 153 sites across 15 countries
  • The P-III INBUILD study results demonstrated that therapy slowed the loss of pulmonary function by 57% (107ml/yr.) across a range of patients while in patients with IP-like fibrotic pattern on HRCT, Ofev slowed the loss of pulmonary function by 61% (128.2ml/yr.)
  • Ofev is a tyrosine kinase inhibitor, approved in 75+ countries for IPF and has received the US FDA’s approval as the first therapy to slow the rate of decline in pulmonary function in patients with SSc-ILD in Sept’2019

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: News-Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post